PRGF -Endoret Technology BTI Implant systems. Scientific Dossier. Prince Felipe Award for Technological Innovation

Transcription

1 PRGF -Endoret Technology BTI Implant systems Scientific Dossier Prince Felipe Award for Technological Innovation

2

3 Introduction Introduction This scientific dossier summarises the series of indexed international articles published over the last 15 years on the range of products and technologies developed by BTI Biotechnology Institute. It highlights the vast amount of scientific evidence that backs the biosafety and effectiveness of plasma rich in growth factors (PRGF -Endoret ) in many fields of medicine, with a particular focus on oral and maxillofacial surgery and oral implantology. This autologous technology has revolutionised the field of personalised regenerative medicine, as with the patient's blood we can obtain different therapeutic formulations rich in growth factors, the application of which encourages healing and tissue regeneration, reducing pain and inflammation. Many publications show the predictability and safety of BTI dental implants and of the surgical techniques (sinus elevation, split, biological drilling, etc) developed under a biological philosophy by Dr. Eduardo Anitua. This dossier also reviews the therapeutic potential of PRGF -Endoret in other fields of medicine in which our research team has been a pioneer at a worldwide level: orthopaedic surgery, treatment of chronic ulcers and facial regeneration, among others. PRGF -Endoret Technology 3

4 What are growth factors and how do they act? Growth factors are a set of substances that carry out an important function in intercellular communication. They carry out a large number of biological functions among which cellular proliferation is important, though they also decisively affect cellular survival, migration, differentiation and even apoptosis. Growth factors carry out their function at very low concentrations in body fluids and tissues, in the region of pico or nanograms. They act by binding to receptors located on the cell membrane that transmit the signal from the exterior to the interior of the cell, through the coupling of different protein kinases that are phosphorylated and which regulate a signalling cascade that ends up with the activation of one or more genes. 4 PRGF -Endoret Technology

5 Growth factors are a set of substances that are fundamental for communication between cells. BTI Biotechnology Institute S.L.

6 How can tissues be regenerated? The process of tissue regeneration includes a complex set of biological events controlled by the action and synergy of a cocktail of growth factors. There are three agents involved in tissue regeneration: the cellular component, a combination of multiple biological mediators that include growth factors and cytokines among others and a matrix or scaffold that gives the new tissue under construction support. After an injury or tissue damage, they are activated and coordinate a large number of intercellular or intracellular paths with the aim of restoring the integrity of the tissue and its hemostasis. Growth factors are also necessary to promote angiogenesis or the formation of blood vessels that will supply oxygen and nutrients to the damaged tissue. Another fundamental aspect to be considered in the regeneration of a tissue is the development of a scaffold that acts as a provisional extracellular matrix and therefore houses the cells as well as locally presenting the biochemical, physical and structural signals that allow the anchorage of the cellular motility machinery. 6 PRGF -Endoret Technology Werner S, Grose R. Regulation of wound healing by growth factors and cytokines. Physiol. Rev. 2003;83:

7 BTI Biotechnology Institute S.L. The tissue regeneration process is based on the combination of cells, growth factors and a matrix or Scaffold. Orive BIOGRAPHY: G, Anitua * Anitua E, et al. E, Biomaterials Sánchez M, Nurden for promoting AT, Nurden brain P, protection, Orive G, Andía repair I. New and insights regeneration. into and Nat Rev novel Neurosci. applications 2009;9: for platelet-rich fibrin therapies. Trends Biotechnol 2006 May;24(5):

8 PRGF -Endoret : A new concept in personalised regenerative medicine Over the last 15 years, the detailed study of platelets, of biological mediators contained in them and of the formulations aimed at allowing the administration and therapeutic use of growth factors and autologous biomaterials has allowed significant progress and has greatly increased the versatility and therapeutic possibilities of Plasma Rich in Growth Factors (PRGF -Endoret ) technology. PRGF -Endoret technology is based on the preparation of platelet-rich 100% autologous plasma the application of which to damaged tissue areas speeds up the regeneration of a large number of tissues without any adverse effects. Plasma rich in growth factors (PRGF - Endoret ) is a personalised technology that has revolutionised the field of regenerative medicine. This article, published in one of the most prestigious journals in the field of biotechnology, summarises the most important clinical results obtained with PRGF -Endoret. Its application over the last decade has extended to many fields of medicine, from oral and maxillofacial surgery to dermatology, cosmetics, orthopaedic surgery and sports medicine, and more recently to ophthalmology. Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol. 2006;24:

9 9 BTI Biotechnology Institute S.L.

10 How is PRGF -Endoret obtained? The set of therapeutic formulations of PRGF -Endoret are obtained by means of a simple protocol based on a tiny volume of the patient's blood. The blood is centrifuged (580g) in 9 ml citrated tubes during 8 minutes allowing the separation of red and white blood cells from the platelet-rich plasma. The two fractions of PRGF -Endoret are separated from the rest of the blood components by means of the plasma transfer device (PTD). Later, and prior to its therapeutic application, the fractions of PRGF -Endoret are activated with calcium chloride, leading to a series of therapeutic formulations. The process to obtain PRGF -Endoret is simple and easily reproducible. DEMONSTRATION VIDEO Scan this code with your mobile phone to watch the video. 10 PRGF -Endoret Technology Anitua E. Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999;14:

11 PRGF -Endoret Technology 11 BTI Biotechnology Institute S.L.

12 Versatility of PRGF -Endoret This article, published in of the most important scientific journals in the field of biomaterials, focuses on the enormous versatility that PRGF -Endoret technology offers, as by using the patient's blood we can obtain up to 4 biocompatible formulations: a. PRGF -Endoret supernatant: used to cultivate primary cells and stem cells in the laboratory, it is also the base of a new collyrium for treating a large number of pathologies of the occular surface. b. Liquid PRGF -Endoret : Ideal for infiltrations in skin, musculoskeletal system tissues, TMJ, etc. It is the perfect tool to bioactivate dental implants and prostheses of all types with the aim of accelerating their osseointegration. c. PRGF -Endoret clot or scaffold : Ideal to fill in defects and promote tissue regeneration: post-extraction, treatment of ulcers, tissue engineering, etc. d. Fibrin membrane: due to its hemostatic properties it is the best biomaterial to seal defects and stimulate epithelisation. 12 PRGF -Endoret Technology Anitua E, Sánchez M, Orive G, Andía I. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials. 2007;28:

13 a b BTI Biotechnology Institute S.L. c d The versatility of PRGF -Endoret technology allows you to obtain up to 4 autologous formulations. BIOGRAPHY: * Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006 May;24(5): PRGF -Endoret Technology 13 02

14 Why does PRGF -Endoret work? The biological activity of the different formulations obtained with PRGF -Endoret technology is based on two fundamental pillars. On the one hand, the content in plasma and in particular platelet growth factors whose action regulates the main processes involved in tissue regeneration. the most important in the field of pharmacology, talks about the therapeutic potential of PRGF -Endoret technology and in particular describes how the perfect synergy between growth factors and fibrin is a key aspect when explaining the clinical results obtained with this autologous technology. On the other, the fibrin matrix, which is used as a provisional structure to house the cells and control the release kinetics of the growth factors present in PRGF -Endoret. Anitua E, Sánchez M, Orive G, Andia I. Delivering growth factors for therapeutics. Trends Pharmacol Sci. 2008;29:37-41 This article published in the prestigious journal Trends in Pharmacological Science, 14 PRGF -Endoret Technology BIOGRAPHY: * Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006 May;24(5):

15 15 BTI Biotechnology Institute S.L.

16 What makes PRGF -Endoret different to other platelet-rich plasmas? PRGF -Endoret is the first 100% autologous platelet-rich plasma to be described in literature worldwide. It is, likewise, a pioneering technology in translational regenerative medicine. Over 15 years of research, added to its exclusive properties, make PRGF -Endoret a unique technique. PRGF -Endoret is prepared with small volumes of the patient's blood and does not require the use of thrombin or chemical agents for its activation. Unlike other products, it does not include white blood cells (leukocytes) in its composition, which gives it more effective anti-inflammatory properties. It is the most versatile technology, as its multiple formulations offer a large number of therapeutic applications. In short, as shown by the series of letters to the editor published during recent years, we can define PRGF -Endoret as a platelet-rich autologous plasma whose effectiveness and safety have been widely proven. However, it is important to remember that not all platelet-rich plasmas are PRGF -Endoret. DEMONSTRATION VIDEO Scan this code with your mobile phone to watch the video. 16 PRGF -Endoret Technology

17 Anitua E, Sánchez M, Orive G, Andía I. Shedding light in the controversial terminology for platelet rich products. J Biomed Mater Res A. 2009;90: Sánchez M, Anitua E, Andia I. Poor standardization in platelet-rich therapies hampers advancement. Arthroscopy. 2010;26: Anitua E, Sánchez M, Orive G. The importance of understanding what is platelet-rich growth factor (PRGF) and what is not. J Shoulder Elbow Surg. 2011;20: Anitua E, Sánchez M, Prado R, Orive G. Plasma rich in growth factors: the pioneering autologous technology for tissue regeneration. J Biomed Mater Res A. 2011;97:536. BTI Biotechnology Institute S.L. Anitua E, Sánchez M, Prado R, Orive G. The P makes the difference in plasma rich in growth factors (PRGF) technology. Platelets. 2011;22: BIOGRAPHY: * Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006 May;24(5): PRGF -Endoret Technology 17 02

18 The pillars of PRGF -Endoret : growth factors PRGF -Endoret contains a cocktail of autologous growth factors that proceed from both the plasma and the platelets. In fact, the platelets have a complex storage system in the form of intracellular granules that allow them to transport a large number of biologically active molecules. According to some authors, this list of proteins and peptides can come close to 500 molecules. Alpha (α) granules are the most abundant as there are around 40 to 80 alpha granules per platelet, but they are also the ones with the greatest retention capacity. In addition, they contain a series of antibacterial proteins that are generically called thrombocidines and which are lethal for a large variety of bacterial species. However, it is important to remember that the plasma contains important growth factors and that the combination of the plasma and platelet factors is a key element in the biological action of PRGF -Endoret. 18 PRGF -Endoret Technology Anitua E, Andia I, Ardanza B, Nurden P, Nurden AT. Autologous platelets as a source of proteins for healing and tissue regeneration. Thromb Haemost. 2004;91:4-15.

19 BTI Biotechnology Institute S.L. El PRGF -Endoret contains hundreds of molecules including plasma and platelet growth factors. BIOGRAPHY: * Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006 May;24(5): PRGF -Endoret Technology 19

20 Platelets and PRGF -Endoret In a couple of revision articles, our research team along with the Nurden Doctors from the Reference Centre for Platelet Disorders in France, have characterised the protein content of platelets in order to learn about the set of molecules present in PRGF -Endoret formulations. factor, EGF: epidermal growth factor or angiopoietin-1 among others. They release in parallel antibacterial molecules and specific growth factors that act on the mobilisation of progenitor cells from the bone marrow or from peripheral niches. Platelets release substances that promote tissue regeneration and which modulate both angiogenesis and inflammation. Important among other factors we have PDGF: plateletderived growth factor, TGF-ß: transforming growth factor ß, bfgf: basic fibroblast growth factor, VEGF: vascular endothelial growth 20 PRGF -Endoret Technology Nurden AT, Nurden P, Sanchez M, Andia I, Anitua E. Platelets and wound healing. Front Biosci. 2008;13:

21 BTI Biotechnology Institute S.L. Platelets release growth factors responsible for coordinating the regenerative tissue response. BIOGRAPHY: * Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006 May;24(5): PRGF -Endoret Technology 21

22 The pillars of PRGF -Endoret : fibrin as a biomaterial Calcium acts as a cofactor in the activation process of PRGF -Endoret, which allows the conversion of the fibrinogen of the plasma into fibrin, generating a gel or clot with important biological functions. On the one hand, fibrin is an excellent matrix to maintain and house the cells, it acts as a provisional scaffold while the definitive tissue is regenerated and acts as a continuous growth factor release system. It is therefore a biocompatible and autologous sponge full of growth factors and cytokines that will permit a progressive release of them during several weeks. The fibrin obtained with PRGF -Endoret technology is probably the best biomaterial for encouraging tissue regeneration. DEMONSTRATION VIDEO Scan this code with your mobile phone to watch the video. 22 PRGF -Endoret Technology Anitua E, Sanchez M, Nurden AT, Zalduendo M, de la Fuente M, Orive G, Azofra J, Andia I. Autologous fibrin matrices: a potential source of biological mediators that modulate tendon cell activities. J Biomed Mater Res A. 2006;77:

23 BTI Biotechnology Institute S.L. BIOGRAPHY: * Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006 May;24(5): PRGF -Endoret Technology 23

24 Biological and regenerative potential of PRGF -Endoret In over a decade of preclinical research, during which tens of cellular phenotypes were studied, we have managed to discover and understand the multiple biological functions that the set of therapeutic formulations of PRGF -Endoret carry out. The biological mediators of PRGF -Endoret stimulate and encourage such important processes for tissue regeneration as cellular proliferation and migration, chemotaxis (or the call from a distance for cells to go to the location of the injury), inflammation and the auto/paracrine synthesis of new molecules with biological activity. DEMONSTRATION VIDEO Scan this code with your mobile phone to watch the video. Anitua E, Sanchez M, Merayo-Lloves J, De la Fuente M, Muruzabal F, Orive G. Plasma rich in growth factors (PRGF-Endoret) stimulates proliferation and migration of primary keratocytes and conjunctival fibroblasts and inhibits and reverts TGF-beta1- Induced myodifferentiation. Invest Ophthalmol Vis Sci. 2011;52: Anitua E, Prado R, Orive G. Bilateral sinus elevation evaluating plasma rich in growth factors technology: a report of five cases. Clin Implant Dent Relat Res. 2012;14:51-60 Bendinelli P, Matteucci E, Dogliotti G, Corsi MM, Banfi G, Maroni P, Desiderio MA. Molecular basis of anti-inflammatory action of platelet-rich plasma on human chondrocytes: mechanisms of NF-κB inhibition via HGF. J Cell Physiol. 2012;225:

25 BTI Biotechnology Institute S.L.

26 PRGF -Endoret in the field of stem cells The growing interest in the range of biological options that PRGF -Endoret offers has even reached the field of stem cells. Stem or progenitor cells are characterised on the one hand by their unlimited capacity for proliferation, and on the other by the possibility of undergoing asymmetrical division (that is, self-renovation) maintaining their stemness while at the same time they can differentiate to diverse types of cells. There are different types of stem cells depending on their origin and their anatomical location. There is evidence that the content of biologically active agents in PRGF -Endoret affects the mobilisation, adhesion, proliferation, survival, activation and differentiation of mesenchymal stem cells and other subtypes of precursor cells. In addition, the cocktail of growth factors of PRGF -Endoret is an ideal resource for the cultivation and expansion of stem cells in the laboratory. 26 PRGF -Endoret Technology

27 BTI Biotechnology Institute S.L. de Boer HC, Verseyden C, Ulfman LH, Zwaginga JJ, Bot I, Biessen EA, Rabelink TJ, van Zonneveld AJ. Fibrin and activated platelets cooperatively guide stem cells to a vascular injury and promote differentiation towards an endothelial cell phenotype. Arterioscler Thromb Vasc Biol. 2006;26: Kajikawa Y, Morihara T, Sakamoto H, Matsuda KI, Oshima Y, Yoshida A, Nagae M, Arai Y, Kawata M, Kubo T. Plateletrich plasma enhances the initial mobilization of circulation-derived cells for tendon healing. J Cell Physiol. 2008;215: Zhang J, Wang JH. Platelet-rich plasma releasate promotes differentiation of tendon stem cells into active tenocytes. Am J Sports Med. 2010;38: Cenni E, Avnet S, Fotia C, Salerno M, Baldini N. Platelet-rich plasma impairs osteoclast generation from human precursors of peripheral blood. J Orthop Res. 2010;28: Chen L, Dong SW, Liu JP, Tao X, Tang KL, Xu JZ. Synergy of tendon stem cells and platelet-rich plasma in tendon healing. J Orthop Res. 2012;30: BIOGRAPHY: * Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006 May;24(5): PRGF -Endoret Technology 27

28 Mechanism of action of PRGF -Endoret The use of growth factors and autologous fibrin for regenerative purposes represents a new approach to personalised medicine that a large number of patients could benefit from. In this paper, published in one of the most important journals of drug delivery, they discuss the mechanisms of action through which PRGF -Endoret produces its multiple therapeutic effects. Likewise, also important is the angiogenic action of the growth factors which is crucial to start regeneration. Last of all, though no less important, its anti-inflammatory and antibacterial properties are a key element. The stimulation of cell proliferation and migration along with the call to circulating cells to come to the location of the injury are basic aspects of the action of PRGF -Endoret. 28 PRGF -Endoret Technology Anitua E, Orive G. Endogenous regenerative technology using plasma- and platelet-derived growth factors. J Control Release. 2012;157:

29 29 BTI Biotechnology Institute S.L.

30 Bacteriostatic potential of PRGF -Endoret Our research team has proven that PRGF -Endoret presents bacteriostatic activity with a large number of bacterial and fungal strains. This is because the platelets contain a series of antibacterial proteins called thrombocidines. These proteins are part of a wider family known as defensins, and they are of a cationic nature, which will allow them to bind to and alter bacterial membranes. In addition to thrombocidines, platelets transport and release other antimicrobial peptides among which we should mention platelet factor 4, RANTES, tissue activating peptide 3, the basic protein of platelets, thymosin β-4, and fibrinopeptides A and B. In a recent paper we could see that the bacteriostatic potential of platelet-rich growth factors is due both to the antimicrobial peptides and to the fibrin, and not to the presence of leukocytes in their composition. In fact, the bacteriostatic effect of PRGF -Endoret is identical to that of a platelet and leukocyte-rich plasma. Another important conclusion of this study was to confirm how the inclusion of leukocytes notably alters the structure and uniformity of the fibrin matrix. 30 PRGF -Endoret Technology Anitua E, Alonso R, Girbau C, Aguirre JJ, Muruzabal F, Orive G. Antibacterial effect of plasma rich in growth factors (PRGF) against Staphylococcus aureus and epidermidis strains. Clin Exp Dermatol. 2012:37:

31 BTI Biotechnology Institute S.L. PRGF -Endoret presents bacteriostatic activity with a variety of bacterial strains. BIOGRAPHY: * Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006 May;24(5): PRGF -Endoret Technology 31

32 Therapeutic applications of PRGF -Endoret This revision article is a reference in international bibliography as it is the journal with the greatest scientific impact. It is about the therapeutic potential of plateletrich plasma, and in this specific case, PRGF - Endoret. This dossier summarises the preclinical and clinical scientific articles that endorse the biosafety and efficacy of PRGF -Endoret in many fields of medicine. The use of growth factors and autologous fibrin for regenerative purposes represents a new approach to personalised medicine that a large number of patients could benefit from. Anitua E, Sánchez M, Orive G. Potential of endogenous regenerative technology for in situ regenerative medicine. Adv Drug Deliv Rev. 2010;62:

33 BTI Biotechnology Institute S.L.

34 Field of Oral Surgery Introduction The versatility of PRGF -Endoret has allowed its use in the treatment of a wide range of clinical problems within the field of oral and maxillofacial surgery. An example of this is the following series of applications developed by our research team over the last two decades and summarised in the scientific dossier. From the treatment of the alveolus post-extraction to the use of this technology in gingival recessions or in the humectation of dental implants to encourage their osseointegration, the range of therapeutic possibilities is enormous. The possibility that PRGF -Endoret offers of working with a liquid formulation, with a three-dimensional matrix or a with retracted fibrin membrane drastically increases the number of therapeutic options and applications. We must not forget that thanks to its agglutinant properties, PRGF -Endoret technology is the perfect fellow traveller to prepare grafts, whether they are autologous bone, allogenic or any other biomaterial for bone regeneration. 34

35 BIOGRAPHY: * Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006 May;24(5): PRGF -Endoret Technology 35

36 Surface bioactivation Preclinical Research In the late 90s Dr. Anitua developed a pioneering technique to humectate implants and bioactivate their surface with fibrin and autologous growth factors. In a simple procedure, the implants are soaked in freshly activated liquid PRGF- Endoret and in this way a fibrin membrane full of growth factors is generated that will encourage a faster osseointegration of the implants. The nano-rough surface of BTI implants is specially designed to boost the biological effects of PRGF -Endoret. DEMONSTRATION VIDEO Scan this code with your mobile phone to watch the video. 36 PRGF -Endoret Technology Anitua EA. Enhancement of osseointegration by generating a dynamic implant surface. J Oral Implantol. 2006;32:72-76.

37 37 BTI Biotechnology Institute S.L.

38 Surface bioactivation Preclinical Research In this study carried out with research animals the aim was to determine whether the humectation of the implant surfaces with PRGF -Endoret encouraged their osseointegration. To this end a total of 23 implants were inserted in the tibia/radius of 3 goats; 13 of them were previously humectated with PRGF -Endoret while the other 10 were not (control). 8 weeks later, a histomorphometric analysis was carried out on the bone biopsies of the sacrificed animals and we observed that the value of the bone-implant contact (BIC) was 51.28% in the animals humectated with PRGF -Endoret, as opposed to 21.89% in the implants that were not humectated, generating a significantly greater area in the former (p<0.01). These results prove how the humectation of implants with PRGF -Endoret encourages their faster osseointegration. 38 PRGF -Endoret Technology Anitua E, Orive G, Pla R, Roman P, Serrano V, Andía I. The effects of PRGF on bone regeneration and on titanium implant osseointegration in goats: a histologic and histomorphometric study. J Biomed Mater Res A. 2009;91:

39 BTI Biotechnology Institute S.L. Humectation of BTI implants with PRGF -Endoret encourages faster osseointegration. BIOGRAPHY: * Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006 May;24(5): PRGF -Endoret Technology 39

40 Surface bioactivation Preclinical Research This new study carried out on research animals evaluated the effect of humectation of dental implants with PRGF -Endoret to encourage and accelerate their osseointegration. To this end 2 dogs were used in which 12 implants were inserted, 6 on each side of the mandible, humectating the implants of one side with PRGF -Endoret, and placing the implants of the opposite side without humectation (control). After 12 weeks, the implants were extracted along with the adjacent bone for a histologicalhistomorphometric analysis. The results showed that the implants humectated with PRGF -Endoret presented higher levels of BIC (bone-impant contact). We also observed higher values of trabecular bone thickness and bone maturity in the areas treated with PRGF -Endoret. Birang R, Tavakoli M, Shahabouei M, Torabi A, Dargahi A, Soolari A. Investigation of peri-implant bone healing using autologous plasma rich in growth factors in the canine mandible after 12 weeks: a pilot study. Open Dent J. 2011;5:

41 BTI Biotechnology Institute S.L. The aim of this study was to assess both the morphology and the composition of the interface formed by the implants activated with PRGF -Endoret. Both features are of capital importance for later regenerative events as both the morphology and the composition of the interface allow the modulation, among other aspects, of the balance between inflammation and regeneration around the implant. In this article we could see through electron, atomic and confocal microscopy that the bioactivation of implants with PRGF - Endoret generates a three-dimensional scaffold with a multitude of platelets, proteins and growth factors. In addition, the composition of the interface of the surfaces bioactivated with PRGF -Endoret is specific, containing platelet and protein elements different to those of other surfaces assessed. The specificity of both the morphology and the composition of the interfaces formed with implants bioactivated with PRGF - Endoret is very possibly the reason behind its beneficial clinical results. Tejero R, Rossbach P, Keller B, Anitua E, Reviakine I. Implant surfaces activated with plasma rich in growth factors: time of flight secondary ion mass spectrometry and principal component analysis study

42 The biological potential of PRGF -Endoret Preclinical Research In this laboratory test we analysed whether the new fraction F2 of PRGF -Endoret produces the same biological effect as the old fraction F3. To this end the potential was evaluated of the different formulations of PRGF -Endoret in the stimulation of different biological processes in human gingival fibroblasts, including the proliferation, migration and adhesión of fibroblasts, as well as the autocrine release of some angiogenic factors and components of the cellular matrix. The results observed showed that PRGF - Endoret significantly increased the cellular proliferation, migration and adhesion of gingival fibroblasts. These results showed how PRGF -Endoret is capable of promoting the regeneration of gingival connective tissue and highlighted the biological potential of the new fraction F2 of PRGF -Endoret. 42 PRGF -Endoret Technology Anitua E, Troya M, Orive G. Plasma Rich in Growth Factors Promotes Gingival Tissue Regeneration by Stimulating Fibroblast Proliferation and Migration and by Blocking TGF-β1-Induced Myodifferentiation. J Periodontol. 2012;83:

43 BTI Biotechnology Institute S.L. In another study carried out on human osteoblasts, again we saw the biological potential of the new fraction F2 of PRGF - Endoret and it was compared to the previous one, F3. To do so we evaluated: proliferation, migration, chemotaxis, autocrine secretion of growth factors and the production of components of the extracellular matrix. The results showed that the new F2 managed to increase the proliferation, migration and chemotaxis of the osteoblasts. In addition, the autocrine expression of two relevant pro-angiogenic factors: VEGF and HGF was significantly improved, and that of three osteoblastic activity markers: procollagen I (PC), osteocalcin (OC) and alkaline phosphatase (ALP). These results showed how the new fraction F2 of PRGF -Endoret stimulates some of the biological processes of the main cells responsible for bone regeneration and its effects are biologically comparable to the previous one, F3. Anitua E, Tejero R, Zalduendo MM, Orive G. Plasma Rich in Growth Factors Promotes Bone Tissue Regeneration by Stimulating Proliferation, Migration and Differentiation of Primary Human Osteoblasts. J Periodontol

44 Biomechanical Studies Preclinical Research This biomechanical study was carried out with the aim of evaluating the influence of straight alignment versus distal offset on the bone stress distribution that the bone around the implant sustains. A mesial load of 200 N and a distal load of 230 N were applied to the prosthesis. These results showed that the fact that there is a limited offset (of up to 2.5 mm) of the prosthesis on the implant does not increase stress on the adjacent bone. The use of larger diameter implants will reduce even further the stress in the bone adjacent to the implant. A controlled offsetting of the implant on the prosthesis, in addition to allowing an optimal aesthetic restoration and reducing the emergence profile, does not increase bone stress and a possible risk of implant failure. 44 PRGF -Endoret Technology Anitua E, Orive G. Finite element analysis of the influence of the offset placement of an implant-supported prosthesis on bone stress distribution. J Biomed Mater Res B Appl Biomater. 2009;89:

45 BTI Biotechnology Institute S.L. The aim of another biomechanical study was to evaluate the influence of the length, diameter and geometry of BTI implants on bone stress distribution. 3D finite element models were created and a load of 150 N was applied at an angle of 30 degrees. Different diameters (3.5 to 5.0 mm) and lengths (8.5 to 15 mm) were evaluated. The results showed that the effect of the implant diameter on bone stress distribution was more significant than the effect of the length or geometry. On the other hand the maximum stress was located around the implant neck and most of it in the bone adjacent to the first implant threads. According to the results observed, the use of greater diameter implants can be beneficial to reduce stress around the implant, meaning that the use of short implants with a greater diameter could be a reasonable alternative in locations where residual bone height is limited. Anitua E, Tapia R, Luzuriaga F, Orive G. Influence of implant length, diameter, and geometry on stress distribution: a finite element analysis. Int J Periodontics Restorative Dent. 2010;30: PRGF -Endoret Technology 45

46 Alveoluses Post- Extraction Clinical Research After the extraction of a tooth a healing and regeneration process starts for the tissues involved that will affect the final volume of alveolar bone and the structure of the ridge. An excessively traumatic extraction or an insufficient regeneration can lead to an excessive loss of bone tissue, a delay in the replacement of lost teeth with implants, may require invasive reconstruction techniques, or may generate a permanent defect without any possible correction. In order to modify this process favourably and to promote adequate regeneration, there are different therapeutic tools among which we could mention those aimed at isolating the defect and preventing the growth of conjunctive tissue towards its interior (membranes), materials susceptible of filling in the defect and substances with osteogenic and osteoconductor properties such as PRGF -Endoret. 46 PRGF -Endoret Technology

47 BTI Biotechnology Institute S.L. The PRGF -Endoret clot is ideal for filling in the alveolus post-extraction and for releasing growth factors that promote its regeneration. 47

48 Alveoluses Post- Extraction Clinical Research This article is the first in scientific literature that describes the use of 100% autologous platelet-rich plasma in oral and maxillofacial surgery. The aim of this pioneering study was to evaluate the use of PRGF -Endoret in the regeneration of alveoluses post-extraction. To carry it out 20 patients were included who were randomly given PRGF -Endoret or the traditional treatment with suture. Biopsies were collected from 6 to 10 weeks after the extraction. The results showed that epithelisation was very good or excellent in the cases treated with PRGF -Endoret and normal in the control group. Regeneration was practically complete in 8 of the 10 cases. The biopsies of the areas treated with PRGF -Endoret showed mature compact bone with well organised trabeculae and normal morphology. In all the biopsies of the control group there was only connective tissue containing bone trabeculae, but in no cases mature bone. The results were significantly better when PRGF -Endoret was used and no adverse effects were observed. Anitua E.Plasma rich in growth factors: preliminary results of use in the preparation of future sites for implants. Int J Oral Maxillofac Implants. 1999;14:

49 BTI Biotechnology Institute S.L. This clinical study was focused on evaluating the clinical results of implants placed immediately in post-extraction sites using PRGF -Endoret as an adjuvant during surgery. A total of 30 patients were included in the study with chronic periapical lesions that required an extraction and a total of 61 implants were placed. Survival and bone loss were assessed 1 year after the implants were placed. The results after an average follow-up period of 18.5 months showed a survival rate of 98.4 %. Average bone loss was 0.41 mm. implants in alveoluses post-extraction can be considered an effective, safe and predictable treatment option in cases with periapical lesions. Del Fabbro M, Boggian C, Taschieri S. Immediate implant placement into fresh extraction sites with chronic periapical pathologic features combined with plasma rich in growth factors: preliminary results of single-cohort study. J Oral Maxillofac Surg. 2009;67: These results prove that the use of PRGF - Endoret for the immediate placement of 49

50 Alveoluses Post- Extraction Clinical Research The aim of this study was to describe and evaluate the use of PRGF -Endoret in the treatment of defects post-extraction. 14 patients were included who required the extraction of different teeth and in 7 of them PRGF -Endoret was applied while in the other 7 it was not, with this being used as the control group. After 11 to 14 weeks, the bone density was measured in the internal and external perimeter as well as in the centre of the defects using the BTI-Scan program. The results showed that bone density in the internal periphery and in the centre of the implant bed was significantly higher in the group treated with PRGF -Endoret with respect to the control group. Bone density was also higher in the external periphery, but without significant differences. As a result we can say that PRGF -Endoret promotes faster bone regeneration in alveoluses post-extraction. DEMONSTRATION VIDEO Scan this code with your mobile phone to watch the video. 50 PRGF -Endoret Technology Anitua et al. Treatment of post-extraction defects using a novel clinical protocol: a case series study. Italian Oral Surgery. 2010;3:

51 1 st day Day 10 BTI Biotechnology Institute S.L. 3 months The application of PRGF -Endoret reduces inflammation and pain, accelerates the epithelisation of soft tissues and promotes bone regeneration. BIOGRAPHY: * Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006 May;24(5): PRGF -Endoret Technology 51

52 Alveoluses Post- Extraction Clinical Research The aim of this split-mouth study was to evaluate the efficacy of PRGF -Endoret in the regeneration of alveoluses post-extraction in impacted third molars. To this end the cytokines in the mucous tissues were analysed after the extraction with the application or not of PRGF -Endoret. Post-op pain and facial swelling were also assessed. The results showed that the inflammation parameters and the regeneration process of the lesion were all significantly better in the areas treated with PRGF -Endoret than in the control areas. On the other hand the post-op pain and facial swelling were less in the areas treated with PRGF -Endoret. In short, based on the results obtained it can be stated that PRGF -Endoret can be routinely used in the regeneration of impacted third molars. Mozzati M, Martinasso G, Pol R, Polastri C, Cristiano A, Muzio G, Canuto R. The impact of plasma rich in growth factors on clinical and biological factors involved in healing processes after third molar extraction. J Biomed Mater Res A. 2010;95: PRGF -Endoret Technology

53 BTI Biotechnology Institute S.L. This article describes a clinical case in which PRGF -Endoret was used to preserve the architecture of the soft tissues associated with an implant that was placed immediately after an extraction at the back of the superior maxilla. This procedure allowed a guided bone regeneration without the need to carry out vertical releasing incisions, presenting a good gingival outline in facial appearance after a single surgical phase. Rosano G, Taschieri S, Del Fabbro M. Immediate post-extraction implant placement using PRGF technology in maxillary premolar region: a new strategy for soft tissue management. J Oral Implantol PRGF -Endoret Technology 53

54 Horizontal and vertical bone regeneration Clinical Research In some situations, there is a lack of bone support due to an atrophy, trauma or surgical resection. As dental implants can only be placed if there is enough bone to be able to adequately stabilise them, the procedures for bone augmentation are an effective therapeutic option for these kinds of situations. In fact, in patients with long-term edentulous sites, even severe bone resorptions are frequently observed (both vertical and horizontal or combined defects). As a result, the use of additional techniques for bone augmentation is essential. Some of these techniques include the use of growth factors, osteogenic distraction, guided bone regeneration, the use of re-vascularised bone grafts and techniques such as ridge expansion or expanders or Split-Crest with ultrasonics. 54 PRGF-ENDORET Technology

55 BTI Biotechnology Institute S.L. The aim of this study was to clinically evaluate the ridge expansion technique with ultrasonics called the Split-Crest technique, for the placement of dental implants in patients with narrow ridges. After at least 6 months after loading the implants, the state of the hard and soft tissues and the expansion achieved were evaluated, as well as the survival rate of the implants. 15 patients were included whose previous average ridge width was 4.29 mm and who received a total of 37 implants. PRGF - Endoret was applied during surgery to encourage tissue regeneration. The results showed that the state of the soft tissues was very good with adequate values of plaque index, bleeding and probing depth. The implant survival rate was 100 %. The average bone expansion achieved was 3.35 mm. These results showed how the Split- Crest technique with ultrasonics along with the application of PRGF -Endoret can be considered an effective and safe technique for bone expansion in narrow ridges. Anitua E, Begoña L, Orive G. Clinical Evaluation of Split-Crest Technique with Ultrasonic Bone Surgery for Narrow Ridge Expansion: Status of Soft and Hard Tissues and Implant Success. Clin Implant Dent Relat Res PRGF -Endoret Technology 55

56 Horizontal and vertical bone regeneration Clinical Research This article rescribes a new ridge expansion technique called the two-stage Split-Crest technique indicated for patients with severely resorbed ridges (3-4 mm). It consists of an expansion carried out in 2 consecutive stages using transitional implants. The implants used as transitional implants (2.5 and 3.0 mm diameter) were replaced from 5 to 7 months after their placement with others with a larger diameter. The state of the soft tissues was good with adequate probing depth values (average value was 3.06 mm). The average bone expansion achieved after the procedure was 8.49 mm apical and 7.10 mm occlusal. There were no implant failures during the follow-up period. These preliminary results prove the predictability and safety of the two-stage Split-Crest technique and its potential use in patients with severely resorbed ridges, as well as avoiding the use of other more aggressive techniques such as bone grafts. DEMONSTRATION VIDEO Scan this code with your mobile phone to watch the video. 56 PRGF -Endoret Technology Anitua E, Begoña L, Orive G. Two-stage split-crest technique with ultrasonic bone surgery for controlled ridge expansion: a novel modified technique.oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011;112:

57 BTI Biotechnology Institute S.L. The new two-stage Split-Crest technique using transitional BTI implants allows an expansion of the ridge of 7-8 mm. Anitua E, Begoña L, Orive, G. Controlled ridge expansion using a two-stage split-crest technique with ultrasonic bone surgery. Implant Dent.2012;21: PRGF -Endoret Technology 57

58 Horizontal and vertical bone regeneration Clinical Research The aim of this randomised clinical test was to evaluate the effectiveness of anorganic bovine bone in ridge expansion with a titanium mesh and to investigate the effect of PRGF -Endoret in preventing mesh exposure, given that it is a frequent complication in these procedures. 30 patients were included on whom a total of 43 ridge expansions were carried out. In 15 of them PRGF -Endoret was used to cover the titanium mesh, while it was not used in the rest (control) the 2 groups regarding the complications and bone formation. In the group treated with PRGF -Endoret there was no mesh exposure while in the control group there was an exposure rate of 28.5%. The radiological analysis showed that bone augmentation was higher in the group with PRGF -Endoret. On the other hand the implant survival rate was 100% in the group with PRGF -Endoret and 97.3% in the control group. After 6 months of evolution, the results showed significant differences between Torres J, et al. Platelet-rich plasma may prevent titanium-mesh exposure in alveolar ridge augmentation with anorganic bovine bone. J Clin Periodontol. 2010;37:

59 BTI Biotechnology Institute S.L. The aim of this randomised clinical trial was to evaluate the use of BTI motorised ridge expanders and to compare their results with those obtained by means of the lateral ridge expansion technique. 8 bilateral patients were included on whom the technique with expanders was applied to one side while on the other the lateral technique was used. The implants were placed 6 months later. The results showed significant differences in the bone expansion achieved with both techniques (1.5 mm with the motorised expanders and 1.2 mm with lateral expansion). These results showed the effectiveness of motorised expanders for the expansion of narrow ridges. In addition, the defects treated with expanders presented less bone width contraction during the first 6 months. Mazzocco F, Nart J, Cheung WS, Griffin TJ. Prospective evaluation of the use of motorized ridge expanders in guided bone regeneration for future implant sites. Int J Periodontics Restorative Dent. 2011;31:

60 Sinus elevation Clinical Research The insertion of implants in the posterior region of the superior maxilla is a difficult clinical procedure. Progressive horizontal and vertical bone resorption increases the sinus cavity while the maxillary sinus floor thickness is reduced. An absence of superior molars can even increase bone resorption, leading to the pneumatisation of the sinus due to an increased activity of osteoclasts in Schneider's membrane. These limitations can make it difficult to place an implant and can negatively affect the success of its osseointegration and the stability of the dental implants. The most frequently applied surgical procedure to reestablish an adequate bone volume and an adequate ridge height in the posterior region of the maxilla is an augmentation of the maxillary sinus. This technique involves the modification of the sinus cavity with the aim of generating sufficient bone volume within a space that used to be part of the sinus cavity. 60 PRGF -Endoret Technology

61 a b BTI Biotechnology Institute S.L. c d The protocol consists of a) carrying out a complete osteotomy with surgical ultrasonics, b) filling in the sinus with a graft soaked in PRGF -Endoret, c) replacing the bone window and a fibrin membrane, and d) placing the implants months later. BIOGRAPHY: * Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006 May;24(5): PRGF -Endoret Technology 61

62 Sinus elevation Clinical Research This article describes the sinus elevation technique with the use of an osteotomy with ultrasonics. This is the first job that uses surgical ultrasonics. This technique offers important advantages over a conventional osteotomy that uses diamond tool bits. In addition, it reduces the risk of perforating Schneider's membrane. On the other hand it improves the vision and hygiene of the surgical area and provides a more conservative and controlled bone incision. The aim of this study was to evaluate a modified sinus elevation technique with osteotomes and the immediate placement of implants and the application of PRGF - Endoret. A total of 14 patients were included on whom this technique was carried out and the results showed that after an average follow-up period of 36 months, none of the implants failed and marginal bone loss after 1 year of load was 0.36 mm. All the treatments were successful. Torrella F, Pitarch J, Cabanes G, Anitua E. Ultrasonic ostectomy for the surgical approach of the maxillary sinus: a technical note. Int J Oral Maxillofac Implants. 1998;13: Taschieri S, Del Fabbro M. Postextraction osteotome sinus floor elevation technique using plasma-rich growth factors. Implant Dent. 2011;20: PRGF -Endoret Technology

63 BTI Biotechnology Institute S.L. The aim of this randomised clinical trial was to evaluate whether PRGF -Endoret improves the effectiveness of inorganic bovine bone in the sinus elevation technique. 87 patients were included on whom a total of 144 sinus elevations were carried out using biomaterial alone or in combination with PRGF -Endoret. A total of 286 implants were placed in the patients, who were monitored for 24 months. The results showed that the survival rate was higher in the implants placed using biomaterial + PRGF -Endoret. It should be noted that in patients with residual ridges of less that 4 mm, the implant survival rate was significantly higher in the areas treated with PRGF -Endoret (98.2 vs 90.7%). The histological and histomorphometric analysis revealed that the bone augmentation was significantly greater in the areas treated with PRGF -Endoret. These results showed that PRGF -Endoret can improve the osteoconductive properties of the biomaterial increasing the volume of new bone formed. Torres J, Tamimi F, Martinez PP, Alkhraisat MH, Linares R, Hernández G, Torres-Macho J, López-Cabarcos E. Effect of plateletrich plasma on sinus lifting: a randomized-controlled clinical trial. J Clin Periodontol. 2009;36: PRGF -Endoret Technology 63

64 Sinus elevation Clinical Research The aim of this study was to describe and evaluate the lateral sinus elevation technique with the application of PRGF -Endoret. 18 patients were included who received a total of 43 implants. All of them presented a residual bone height of 1-3 mm. The technique consisted of carrying out a vestibular osteotomy with ultrasonics, separating the window created and keeping it submerged in PRGF -Endoret. Once the elevation is carried out the window is replaced in its anatomical location and covered with autologous fibrin. After 6 months the samples of bone taken from the sinuses were evaluated. The results showed that after an average follow-up period of 13 months, the implant survival rate was 100%. These results showed that the lateral sinus elevation technique using PRGF -Endoret can be considered a safe, effective and predictable technique. DEMONSTRATION VIDEO Scan this code with your mobile phone to watch the video. 64 PRGF -Endoret Technology Anitua E, Prado R, Orive G. A lateral approach for sinus elevation using PRGF technology. Clin Implant Dent Relat Res. 2009;11:23-31.

65 PRGF -Endoret Control BTI Biotechnology Institute S.L. Regenerative potential after 5 months and anti-inflammatory properties of PRGF -Endoret. The aim of this study was to evaluate the potential effect of PRGF -Endoret in the lateral approach for sinus elevation. 5 patients were included who required bilateral sinus elevations with a residual bone height of 1-3 mm. On one side PRGF - Endoret was used along with inorganic bovine bone, while only biomaterial was used on the other side. The use of PRGF -Endoret doubled the volume of the graft thanks to the action of the fibrin. Post-op pain and inflammation were greater on the control side (without PRGF -Endoret ). The areas treated with PRGF -Endoret presented a larger amount of new vital bone than those without. The immunohistochemistry of the biopsies revealed that the number of blood vessels per square millimetre of connective tissue was 116 vessels as opposed to 7 in the control areas. These results showed the therapeutic potential of PRGF -Endoret for reducing inflammation, increasing new bone formed and generating blood vessels in these sinus elevation procedures. Anitua E, Prado R, Orive G. Bilateral Sinus Elevation Evaluating Plasma Rich in Growth Factors Technology: A Report of Five Cases. Clin Implant Dent Relat Res. 2012;14:

66 Bisphosphonate-related osteonecrosis of the jaw Clinical Research Biphosphonates are a group of drugs that reduce the rate of bone turnover, mainly through the inhibition of the action of osteoclasts, and they are administered both orally and intravenously in patients with oncological or rheumatic treatments. These drugs show calcium affinity and their mechanism of action at a cellular level includes the inhibition of the vascular endothelial growth factor (VEGF). Around the year 2003 the first cases of exposed bone that would not heal in the maxillofacial region in patients treated with intravenous biphosphonates were reported, meaning that this pathology was associated with the administration of biphosphonates and was identified as bisphosphonaterelated osteonecrosis of the jaw (BRONJ). The accumulated incidence of BRONJ has been estimated within a range of 8 to 12%, for IV administration and 0.7/100,000 people/year for oral administration. To date, the treatments available to prevent or treat BRONJ are very limited and the results obtained are not conclusive. Recently, the use of PRGF -Endoret has been proposed as part of a preventive and therapeutic approach. The hypothesis of the use of this autologous technology is based on the potential effects of the growth factors released in the osteoclasts and on angiogenesis. 66 PRGF -Endoret Technology

67 BTI Biotechnology Institute S.L. This article describes the clinical case of a patient affected by BRONJ after being treated for several years with zoledronic acid (IV) and after a tooth extraction. Their symptomatology includes severe pain and hemimandibular paresthesia due to affectation of the dental nerve. The treatment consisted of surgical resection of the necrotic bone area combined with the application of PRGF -Endoret. improvement of the pain and paresthesia was observed. After a year, the patient had totally recovered sensitivity and the absence of necrotic bone was confirmed. These clinical results support the use of PRGF -Endoret as an adjuvant treatment for patients with BRONJ. One month after surgery, total closure of the ulcerous lesion in the mucous membrane was observed without the presence of necrotic bone. 6 months later, a significant Anitua et al.treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with plasma rich in growth factors (PRGF- ENDORET). Br J Oral Maxillofac Surg PRGF -Endoret Technology 67

68 Bisphosphonate-related osteonecrosis of the jaw Clinical Research The aim of this study was to describe and evaluate the use of PRGF -Endoret within the surgical tooth extraction protocol for patients in treatments with biphosphonate drugs and its role in the prevention of bisphosphonate-related osteonecrosis of the jaw (BRONJ). A total of 64 patients were included on whom a total of 220 extractions were carried out and in all of them PRGF - Endoret was applied to cover the defect and to encourage a correct regeneration of tissues. The patients were monitored for at least 4 months. Bisphosphonate-related osteonecrosis of the jaw only occurred in 5 post-extraction sites (2.27%). In the mandible, the cases of BRONJ were more frequent. The results of this study show that PRGF -Endoret is a possible alternative to prevent these lesions in patients in treatment with biphosphonates who have had dental extractions. Scoletta M, Arduino PG, Pol R, Arata V, Silvestri S, Chiecchio A, Mozzati M. Initial experience on the outcome of teeth extractions in intravenous bisphosphonate-treated patients: a cautionary report. J Oral Maxillofac Surg. 2011;69:

69 The aim of this study of case and control groups was to determine the role of PRGF -Endoret in the prevention of bisphosphonate-related osteonecrosis of the jaw in patients who took IV biphosphonates and who had dental extractions. The study included 100 patients, of whom 50 received PRGF -Endoret after the extraction while the rest did not receive PRGF -Endoret (control group). The patients were monitored for a period ranging between 24 and 60 months, carrying out annual checkups and scans. BRONJ was diagnosed in 2 patients and both were from the control group. Despite the small number of patients, these results may suggest that treatment of extractions with PRGF -Endoret may reduce the risk of developing BRONJ by these patients at risk receiving treatment with IV biphosphonates. Mozzati M, Arata V, Gallesio G, Carossa S. A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case-control study. Joint Bone Spine. 2011;78:

70 Bisphosphonate-related osteonecrosis of the jaw Clinical Research The effectiveness of plasma rich in growth factors (PRGF -Endoret ) in the treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ) was studied in 32 patients, with an average age of 69.7 years. The patients suffered a IIB type BRONJ lesion according to the Marx classification. All the patients took intravenous biphosphonates during an average period of 37 months when they were diagnosed with a BRONJ lesion. The treatment chosen includes a surgical resection of the lesion up to bleeding margins. PRGF -Endoret technology allowed obtaining a fibrin clot rich in growth factors to fill in the bone defect and obtaining a fibrin membrane to cover the defect and close the dehiscence in the soft tissue. The total follow-up period was 48 to 50 months. The results clearly showed the effectiveness of PRGF -Endoret in solving the BRONJ lesion. No intra or post-op complications were registered. The treatment of the lesion consists of closing the mucous dehiscence without any clinical or radiological sign of an infection or bone exposure. 70 PRGF -Endoret Technology Mozzati M, Gallesio G, Arata V, Pol R, Scoletta M. Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases. Oral Oncol May;48(5):

71 a b c d The application of PRGF -Endoret in the treatment of BRONJ improves the closure of soft tissues and the regeneration of the bone defect. PRGF -Endoret is effective in the treatment of BRONJ as it promotes angiogenesis and encourages the regeneration of bone and epithelial tissue.

72 Bisphosphonate-related osteonecrosis of the jaw Clinical Research The extraction of teeth is the main cause of biphosphonate-related osteonecrosis of the jaw (BRONJ). The efficacy and safety of plasma rich in growth factors (PRGF -Endoret ) in different applications has encouraged its application in preventing the development of BRONJ after a tooth extraction. In this study, 176 patients were recruited who took zoledronic acid and required the extraction of teeth. Before the tooth extraction the patients received oral hygiene and antibiotic treatment sessions. The patients were randomised in two groups: the first (91 patients) received the PRGF - Endoret treatment while the second (85 patients) were used as the control group. The PRGF -Endoret treatment includes filling in the alveolus post-extraction with a clot rich in growth factors and covering the surgical area with a fibrin membrane before closing the flap. PRGF -Endoret was shown to be effective in preventing the development of BRONJ in 542 extractions. On the other hand, in the control group 5 out of 267 extractions developed a BRONJ lesion as indicated by the presence of a bone exposure. The average period for the development of this lesion was 91.6 days after the tooth extraction. 72 PRGF -Endoret Technology Mozzati M, Arata V, Gallesio G. Tooth extraction in patients on zoledronic acid therapy. Oral Oncol ;48:

73 The use of PRGF -Endoret in the treatment of alveoluses post-extraction prevents against the development of BRONJ in patients treated with biphosphonates. PRGF -Endoret reduces the risk of BRONJ in patients treated with biphosphonates who require a tooth extraction. BIOGRAPHY: * Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006 May;24(5): PRGF -Endoret Technology 73

74 BTI implants Clinical Research The range of BTI implants presents a series of special and differential features. All of them have a surface treatment that gives them excellent humectability, thus obtaining a nanometric bioactive surface ideal in combination with PRGF -Endoret to shorten their osseointegration periods. On the other hand, their surface provides an excellent titanium-bone interface and maximum bone apposition is achieved with an increase of BIC (bone-implant contact). Its self-tapping apex with excellent advancing capacity and small apical surface avoids compressions and facilitates its directional control and placement in narrow ridges. Within the range of BTI implants, we should highlight the family of short ( 8.5 mm) and extra-short ( 6,5 mm) implants that have proven their high long-term predictability. 74 PRGF -Endoret Technology Anitua E. Novel protocols for predictable implantology. Pract Proced Aesthet Dent. 2008;20:

75 This retrospective study with BTI implants was published in the journal with the greatest scientific impact in the field of dentistry. Its aim was to evaluate the long-term survival of BTI implants and to identify the possible risk factors associated with implant failures. A total of 5787 BTI implants of different diameters and lengths were included in the study. The results showed that the implant survival rate was 99.2%, 96.4% and 96.0% for the analysis based on the implant, on the surgery and on the patient, respectively. The risk factors that could be related to a higher implant failure rate were two-stage surgery and the use of special surgery-related techniques. These results attest to the predictability and safety of BTI's range of implants. Anitua E, Orive G, Aguirre JJ, Ardanza B, Andía I. 5-year clinical experience with BTI dental implants: risk factors for implant failure. J Clin Periodontol. 2008;35: PRGF -Endoret Technology 75

76 BTI implants Immediate load This study was carried out with the aim of describing the immediately loaded dental implant insertion technique and to evaluate the long-term survival, as well as the possible risk factors related to its failure. A total of 1139 implants were included and a survival rate of 99.3%, 96.8% and 96.9% was observed for the analysis based on the implant, on the surgery and on the patient, respectively. Only 5 of the implants failed during the follow-up period and no failure-related risk factors were found. These results showed the predictability of the immediate load technique described provided it is used with appropriate insertion torques and following strict clinical protocols. 76 PRGF -Endoret Technology Anitua E, Orive G, Aguirre JJ, Andía I. Clinical outcome of immediately loaded dental implants bioactivated with plasma rich in growth factors: a 5-year retrospective study. J Periodontol. 2008;79:

77 Short implants Several years after starting the clinical use of short implants, the decision was made to carry out this study, the aim of which was to evaluate the long-term survival of short BTI implants ( 8.5 mm) in posterior areas of the superior maxilla and the mandible. A total of 532 implants placed in 293 patients were included. The results showed a survival rate of 99.2% and 98.7% for the analysis based on the implant and on the patient, respectively. Two of the implants failed due to different causes after an average follow-up period of 31 months. No risk factors related to the failure of the short implants could be identified. These results showed the high predictability of the use of short implants in posterior areas. Anitua E, Orive G, Aguirre JJ, Andía I. Five-year clinical evaluation of short dental implants placed in posterior areas: a retrospective study. J Periodontol. 2008;79: PRGF -Endoret Technology 77

78 BTI implants Short implants The aim of these studies was to evaluate the long-term survival (up to 8 years of followup) of short and extra-short BTI implants ( 8.5 mm) in posterior areas of the superior maxilla and the mandible. In the first of them, a total of 1287 short implants placed in 661 patients were included. The results showed a survival rate of 99.3% and 98.8% for the analysis based on the implant and on the patient, respectively. Nine of the implants failed due to different causes. No risk factors related to the failure of the short implants could be identified. ( 6,5) were also studied separately, showing survival rates of 97.9% and 97.1% for the implants and patients, respectively. These results showed that treatment with short and extra-short implants can be considered a safe and predictable technique if used following strict clinical protocols. In the second study the extra-short implants 78 PRGF -Endoret Technology Anitua E, Orive G. Short implants in maxillae and mandibles: a retrospective study with 1 to 8 years of follow-up. J Periodontol. 2010;81:

79 a b BTI Biotechnology Institute S.L. c d Short and extra-short implants allow rehabilitations in atrophic ridges without having to resort to more aggressive techniques such as bone grafts. Anitua E. The Use of Short and Extra-Short BTI Implants In the Daily Clinical Practice. JIACD 2010;2: PRGF -Endoret Technology 79

80 BTI implants Short implants This study was carried out with the aim of evaluating the influence of an unfavourable crown/implant ratio ( 1) and other variables of the implant, be they surgical, prosthetic or biomechanical, on Marginal Bone Loss and on the survival of short implants in posterior areas. A total of 128 implants placed in 63 patients were evaluated. The average followup period was 22 months. The average C/I ratio of the implants was In 86 of them it was <2 and in 42 implants 2. The marginal bone loss observed was 0.35 mm during the first year post-load and 0.45 mm after the first year post-load. The implant and prosthesis survival rate was 100 %. The unfavourable C/I ratio did not show any relationship with the marginal bone loss of the implants. Of the remaining variables studied, the only one that showed a negative inflluence was the use of cantilevers in prosthetic rehabilitations. Anitua E, Begoña L, Piñas L, Orive, G. Impact of unfavorable crown-to-implant ratio on marginal bone loss and survival rates of short and extra-short implants placed in posterior regions PRGF -Endoret Technology

81 BTI Biotechnology Institute S.L. The aim of this study was to evaluate the influence of a very unfavourable crown/ implant ratio ( 2) and other variables, be they surgical, prosthetic or biomechanical, on Marginal Bone Loss and on the survival of short implants in posterior areas. A total of 42 implants placed in 28 patients were evaluated. The average follow-up period was 28 months. The average C/I ratio of the implants was The marginal bone loss observed was 0.38 mm and 0.24 mm mesial and distal, respectively. The implant and prosthesis survival rate was 100 %. The very unfavourable C/I ratio did not show any relationship with the marginal bone loss of the short implants in posterior areas. No relationship was found between the rest of the variables studied and marginal bone loss. Anitua E, Begoña L, Piñas L, Orive, G. Short and extra-short implants with a very unfavorable crown-to-implant ratio ( 2) in posterior regions. Influence on marginal bone loss and survival rate PRGF -Endoret Technology 81

82 BTI implants Narrow implants This study was carried out to evaluate the long-term survival and clinical effectiveness of narrow-diameter (2.5 and 3.0 mm) BTI Tiny implants in patients with an insufficient ridge (2.5 to 4.0 mm) to allow the placement of standard-diameter implants. 51 patients were included who received a total of 89 implants. The results showed a survival rate of 98.9% and 98.0% for the analysis based on the implant and on the patient, respectively. Only one implant failed 12 months after its placement. Average bone loss after 2 years of implant load was 1.26 mm. These results showed that 2.5 and 3.0 mm Tiny implants can be used effectively and safely for the treatment of narrow and severely resorbed ridges. 82 PRGF -Endoret Technology Anitua E, Errazquin JM, de Pedro J, Barrio P, Begoña L, Orive G. Clinical evaluation of Tiny 2.5- and 3.0-mm narrow-diameter implants as definitive implants in different clinical situations: a retrospective cohort study. Eur J Oral Implantol. 2010;3:

83 BTI Biotechnology Institute S.L. The many clinical studies carried out with BTI implants prove their versatility, safety and predictability 83

84 BTI implants Implant explantation This article describes for the first time the concept of de-osseointegration of implants. For this purpose a new technique has been developed that uses the BTI Explantation Kit, which facilitates an easy and atraumatic explantation while keeping the walls of the alveolar bed intact to allow the placement of a new implant. In this study a total of 58 explantation cases of different implants were included using the BTI Explantation Kit. The removal torque varied between 80 and 200 Ncm. In 20 cases a new implant was placed. This article shows how the possibility of explanting dental implants atraumatically opens new doors in oral implantology. DEMONSTRATION VIDEO Scan this code with your mobile phone to watch the video. Anitua et al. Atraumatic Implant Explantation, is it Possible? Description of a Novel Technique and a Case Series Study. JIACD 2010;2: PRGF-ENDORET Technology

85 BTI Biotechnology Institute S.L. This study was carried out with the aim of describing and evaluating the new technique for the atraumatic explantation of implants. This new technique facilitates a fast explantation, keeping the alveolar bed walls intact and at the same time facilitating the insertion of a new implant during the same surgical operation. In this study 91 implants explanted from a total of 42 patients were included. The removal torques varied between 80 and 200 Ncm. In those cases where the implant removal torque exceeded 200 Ncm, 2-3 mm incisions were carried out with a set of atraumatic trephines to avoid excessively high torques. These results showed how the possibility of explanting implants atraumatically can be considered a viable alternative to replace failed implants. Anitua et al. A new approach for atraumatic implant explantation and immediate implant installation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2012;113:19-25 PRGF -Endoret Technology 85

86 BTI implants Antibiotic prophylaxis for implants The aim of this randomised clinical trial was to assess the need or not to administer an antibiotic prophylaxis with 2 g of oral amoxicillin one hour before the single dental implant insertion surgery to avoid post-op infections. 12 private centres which recruited a total of 105 patients took part. 52 patients received amoxicillin and 53 received a placebo. After 6 months, there were 6 infections and 2 implant failures in each group. No statistically significant differences were found for post-op infections, adverse events or implant failures between both groups. Observing the results of this study, antibiotic prophylaxis for single implants may not be necessary. DEMONSTRATION VIDEO Scan this code with your mobile phone to watch the video. 86 PRGF -Endoret Technology Anitua E, Aguirre JJ, Gorosabel A, Barrio P, Errazquin JM, Román P, Pla R, Carrete J, de Petro J, Orive G. A multicentre placebo-controlled randomised clinical trial of antibiotic prophylaxis for placement of single dental implants. Eur J Oral Implantol. 2009;2:

87 BTI Biotechnology Institute S.L. Biological drilling In this article, the aim was to describe and compare with the traditional drilling system a low-revolution drilling system ( r.p.m) that allows surgeons to obtain live autologous bone that can be associated with PRGF -Endoret to be used in bone grafts. Bone particles using both conventional techniques and the new low-revolution drillling system were collected and analysed under a microscope. The microscopic examination showed that the bone structure and the presence of live cells was preserved in all the samples collected with low-revolution drilling while these qualities were not maintained with conventional drilling. This new drilling technique can reduce damage to the host tissue and can be used to obtain a mass of live bone ideal for carrying out bone grafts associated with PRGF -Endoret. Anitua E, Carda C, Andia I. A novel drilling procedure and subsequent bone autograft preparation: a technical note. Int J Oral Maxillofac Implants. 2007;22: PRGF -Endoret Technology 87

88 Facial regeneration Aging is a multi-factorial process that is characterised by a progressive reduction of the functional capacity of all the body's tissues and organs, with the consequent loss of ability to adjust to environmental stimuli. It is a known fact that skin aging is produced by cellular or intercellular matrix degradation, reduced vascularisation, a dysfunction of skin annexes, fat atrophy and muscular atrophy or relaxation. These phenomena are fundamentally influenced by the inexorable passage of time and genetics, in addition to other factors such as sun exposure, diseases, nutrition, toxic habits, etc. The most evident signs of aging are wrinkles, dyschromias and ptosis, and other less evident ones, such as the texture, feel, colour, shine and brightness, which globally determine the final appearance of the skin. Today, and due to social pressure, increasing importance is given to our physical appearance, where it is considered acceptable and even necessary in more and more circles to struggle to maintain a youthful and healthy appearance. This growing aesthetic awareness means that the interest in developing new products to help us improve the appearance of our skin has increased. 88

89 BTI Biotechnology Institute S.L. PRGF -Endoret represents the first biological therapy for personalised medicine that has proved its effectiveness in facial regeneration and anti-aging. 89

90 Facial regeneration Clinical research In this randomised clinical trial the effectiveness and safety of PRGF -Endoret was evaluated in the cutaneous regeneration of aged skin, comparing it with hyaluronic acid. A total of 100 patients were included with evident external signs of aged skin and were randomly assigned treatment with PRGF - Endoret or with hyaluronic acid. The level of skin moisturisation, cutaneous concentration of fat and skin ph, the level of severity of the wrinkle and patient satisfaction were evaluated. The results showed that in both follow-up visits the skin moisturisation and ph values as well as the satisfaction rate were significantly higher in the group treated with PRGF - Endoret (p<0.05) than in the control group. On the other hand, the fat index drop after 3 months was significantly lower in both groups with respect to the baseline visit. These results support the application of PRGF -Endoret in the treatment of age-related skin aging, obtaining excellent mid and long-term results after its application. 90 PRGF -Endoret Technology

91 BTI Biotechnology Institute S.L. Anitua E, Sánches M, Sarabia R, Sanz J, Aguirre JJ, Orive G. Eficacia y seguridad del PRGF (plasma rico en factores de crecimiento) en la regeneración cutánea facial. Ensayo clínico, randomizado y controlado con ácido hialurónico. Journal of the AECEP. 2011: DEMONSTRATION VIDEO Scan this code with your mobile phone to watch the video. before after PRGF -Endoret Technology 91

92 Publications Traumatology, orthopaedic surgery and sports medicine Revision articles Sánchez M, Anitua E, Orive G, Mujika I, Andia I. Platelet-rich therapies in the treatment of orthopaedic sport injuries. Sports Med. 2009;39: Engebretsen L, Steffen K, Alsousou J, Anitua E, Bachl N, Devilee R, Everts P, Hamilton B, Huard J, Jenoure P, Kelberine F, Kon E, Maffulli N, Matheson G, Mei-Dan O, Menetrey J, Philippon M, Randelli P, Schamasch P, Schwellnus M, Vernec A, Verrall G. IOC consensus paper on the use of plateletrich plasma in sports medicine. Br J Sports Med. 2010;44: Sánchez M, Anitua E, Lopez-Vidriero E, Andía I. The future: optimizing the healing environment in anterior cruciate ligament reconstruction. Sports Med Arthrosc. 2010;18: Andia I, Sanchez M, Maffulli N. Tendon healing and platelet-rich plasma therapies. Expert Opin Biol Ther. 2010;10: Mei-Dan O, Lippi G, Sánchez M, Andia I, Maffulli N. Autologous platelet-rich plasma: a revolution in soft tissue sports injury management? Phys Sportsmed. 2010;38: Andia I, Sánchez M, Maffulli N. Platelet rich plasma therapies for sports muscle injuries: any evidence behind clinical practice? Expert Opin Biol Ther. 2011;11: Andia I, Sánchez M, Maffulli N. Joint pathology and platelet-rich plasma therapies. Expert Opin Biol Ther. 2012;12:7-22. Preclinical Research Anitua E, Andía I, Sanchez M, Azofra J, del Mar Zalduendo M, de la Fuente M, Nurden P, Nurden AT. Autologous preparations rich in growth factors 92 PRGF -Endoret Technology

93 BTI Biotechnology Institute S.L. promote proliferation and induce VEGF and HGF production by human tendon cells in culture. J Orthop Res. 2005;23: Anitua E, Sanchez M, Nurden AT, Zalduendo M, de la Fuente M, Orive G, Azofra J, Andia I. Autologous fibrin matrices: a potential source of biological mediators that modulate tendon cell activities. J Biomed Mater Res A. 2006;77: Sánchez M, Anitua E, Azofra J, Andía I, Padilla S, Mujika I. Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. Am J Sports Med. 2007;35: Anitua E, Sanchez M, Nurden AT, Zalduendo M, de la Fuente M, Azofra J, Andia I. Reciprocal actions of platelet-secreted TGF-beta1 on the production of VEGF and HGF by human tendon cells. Plast Reconstr Surg. 2007;119: Anitua E, Sánchez M, Nurden AT, Zalduendo MM, de la Fuente M, Azofra J, Andía I. Platelet-released growth factors enhance the secretion of hyaluronic acid and induce hepatocyte growth factor production by synovial fibroblasts from arthritic patients. Rheumatology (Oxford). 2007;46: Anitua E, Sánchez M, Zalduendo MM, de la Fuente M, Prado R, Orive G, Andía I. Fibroblastic response to treatment with different preparations rich in growth factors. Cell Prolif. 2009;42: Gallo I, Sáenz A, Artiñano E, Esquide J. Autologous platelet-rich plasma: effect on sternal healing in the sheep model. Interact Cardiovasc Thorac Surg. 2010;11: Anitua E, Sanchez M, De la Fuente M, Zalduendo MM, Orive G. Plasma rich in growth factors (PRGF-Endoret) stimulates tendon and synovial fibroblasts migration and improves the biological properties of hyaluronic acid. Knee Surg Sports Traumatol Arthrosc ;20: PRGF -Endoret Technology 93

94 Publications Traumatology, orthopaedic surgery and sports medicine Clinical Research Sánchez M, Azofra J, Aizpurúa B, Elorriaga R, Anitua E, Andía I. Aplicación de plasma autólogo rico en factores de crecimiento en cirugía artroscópica - Use of autologous plasma rich in growth factors in Arthroscopic surgery. Cuadernos de Artroscopia 2003;10: Sánchez M, Azofra J, Anitua E, Andía I, Padilla S, Santisteban J, Mujika I. Plasma rich in growth factors to treat an articular cartilage avulsion: a case report. Med Sci Sports Exerc. 2003;35: Sánchez M, Anitua E, Azofra J, Aguirre JJ, Andia I. Intra-articular injection of an autologous preparation rich in growth factors for the treatment of knee OA: a retrospective cohort study. Clin Exp Rheumatol. 2008;26: Sánchez M, Anitua E, Cole A, Da Silva A, Azofra J, Andia I. Management of post-surgical Achilles tendon complications with a preparation rich in growth factors: A study of two-cases. Injury Extra. 2009;40: Jiménez-Martin A, Angulo-Gutiérrez J, González- Herranz J, Rodriguez-De La Cueva JM, Lara-Bullón J, Vázquez-Garcia R. Surgery of subacromial syndrome with application of plasma rich in growth factors. Int J Shoulder Surg. 2009;3: Anitua E, Sánchez M, de la Fuente M, Azofra J, Zalduendo M, Aguirre JJ, Andía I. Relationship between Investigative Biomarkers and Radiographic Grading in Patients with Knee Osteoarthritis. Int J Rheumatol. 2009;2009: Sanchez M, Anitua E, Cugat R, Azofra J, Guadilla J, Seijas R, Andia I. Nonunions treated with autologous preparation rich in growth factors. J Orthop Trauma. 2009;23: Seijas R, Santana-Suarez RY, Garcia-Balletbo M, Cuscó X, Ares O, Cugat R. Delayed union of the cla- 94 PRGF -Endoret Technology

95 PRGF -Endoret has been a pioneer proving its effectiveness in the treatment of osteoarthritis and tendinopathies vicle treated with plasma rich in growth factors. Acta Orthop Belg. 2010;76: Sánchez M, Anitua E, Azofra J, Prado R, Muruzabal F, Andia I. Ligamentization of tendon grafts treated with an endogenous preparation rich in growth factors: gross morphology and histology. Arthroscopy. 2010;26: Mei-Dan O, Carmont M, Kots E, Barchilon V, Nyska M, Mann G. Early return to play following complete rupture of the medial collateral ligament of the elbow using preparation rich in growth factors: a case report. J Shoulder Elbow Surg. 2010;19:e1-e5. Wang-Saegusa A, Cugat R, Ares O, Seijas R, Cuscó X, Garcia-Balletbó M. Infiltration of plasma rich in growth factors for osteoarthritis of the knee shortterm effects on function and quality of life. Arch Orthop Trauma Surg. 2011;131: Sánchez M, Guadilla J, Fiz N, Andia I. Ultrasoundguided platelet-rich plasma injections for the treatment of osteoarthritis of the hip. Rheumatology (Oxford). 2012;51: Guadilla J, Fiz N, Andia I, Sánchez M. Arthroscopic management and platelet-rich plasma therapy for avascular necrosis of the hip. Knee Surg Sports Traumatol Arthrosc ;20: Filardo G, Kon E, Pereira Ruiz MT, Vaccaro F, Guitaldi R, Di Martino A, Cenacchi A, Fornasari PM, Marcacci M. Platelet-rich plasma intra-articular injections for cartilage degeneration and osteoarthritis: single- versus double-spinning approach. Knee Surg Sports Traumatol Arthrosc. 2012;20: Sánchez M, Fiz N, Azofra J, Usabiaga J, Arduriz Recalde E, García Gutierrez A, Albillos J, Gárate R, Aguirre JJ, Padilla S, Orive G, Anitua E. A randomized clinical trial evaluating plasma rich in growth factors (PRGF-Endoret) versus Hyaluronic acid in the short-term treatment of symptomatic knee osteoarthritis. Arthroscopy.2012;28: PRGF -Endoret Technology 95

96 Publications Dermatology Anitua E, Sánchez M, Nurden AT, Nurden P, Orive G, Andía I. New insights into and novel applications for platelet-rich fibrin therapies. Trends Biotechnol 2006;24: Anitua E, Sánchez M, Orive G, Andía I. The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. Biomaterials 2007;28: Anitua E, Sánchez M, Orive G, Andia I. Delivering growth factors for therapeutics. Trends Pharmacol Sci. 2008;29:37-41 Anitua E, Sánchez M, Orive G. Potential of endogenous regenerative technology for in situ regenerative medicine. Adv Drug Deliv Rev 2010;62: Preclinical Research Molina-Miñano F, López-Jornet P, Camacho- Alonso F, Vicente-Ortega V. The use of plasma rich in growth factors on wound healing in the skin: experimental study in rabbits. Int Wound J. 2009;6: Clinical Research Anitua E, Aguirre JJ, Algorta J, Ayerdi E, Cabezas AI, Orive G, Andia I. Effectiveness of autologous preparation rich in growth factors for the treatment of chronic cutaneous ulcers. J Biomed Mater Res B Appl Biomater. 2008;84: Orcajo B, Muruzabal F, Isasmendi MC, Gutierrez N, Sánchez M, Orive G, Anitua E. The use of plasma rich in growth factors (PRGF-Endoret) in the treatment of a severe mal perforant ulcer in the foot of a person with diabetes. Diabetes Res Clin Pract. 2011;93:e65-e67. Aguirre JJ et al. Eficacia del PRGF en el tratamiento de las úlceras cutáneas secundarias a insuficiencia venosa: Ensayo clínico aleatorizado controlado con tratamiento convencional

97 97 BTI Biotechnology Institute S.L.

98 98

99 99

100 USA 1730 Walton Road Suite 110 Blue Bell, PA USA Tel: (12) Fax: (12) Cat.031-ING - Ed.2 - Rev.1 OCT2012 UK 870 The Crescent Colchester Business Park Colchester Essex CO49YQ United Kingdom Tel: (44) Fax: (44) info@bti-implant.co.uk GERMANY Mannheimer Str Pforzheim Germany Tel: (49) Fax: (49) info@bti-implant.de ITALY Piazzale Piola, Milan Italy Tel: (39) Fax: (39) bti.italia@bti-implant.it BTI Biotechnology Institute San Antonio, 15 5º Vitoria-Gasteiz (Álava) SPAIN Tel: Fax: bti@bticomercial.com MEXICO Ejercito Nacional Mexicano 351, 3A Col. Granada Delegación Miguel Hidalgo México DF CP Mexico Tel: (52) Fax: (52) bti.mexico@bti-implant.com PORTUGAL Praça Mouzinho de Albuquerque, 113, 5º Porto PORTUGAL Tel: (351) Fax: (351) bti.portugal@bticomercial.com BTI RESEARCH BIOTECHNOLOGY INSTITUTE SCAN THIS CODE with your mobile phone and to access all the information of BTI Biotechnology Institute.